Cmpd17b Lowers Blood Pressure at 50 mg/kg and Reverses Kidney Fibrosis in Hypertensive Mice
Updated
Updated · Nature.com · Aug 13
Cmpd17b Lowers Blood Pressure at 50 mg/kg and Reverses Kidney Fibrosis in Hypertensive Mice
1 articles · Updated · Nature.com · Aug 13
Summary
28 days of Cmpd17b treatment selectively lowered blood pressure in BPH/2 J hypertensive mice, while leaving blood-pressure-normal mice largely unaffected.
At 50 mg/kg/day, the FPR agonist also improved aortic distensibility and cut collagen deposition across organs, with the strongest anti-fibrotic effect seen in the kidney.
RNA sequencing linked that kidney response to abnormal Serpina1e and Igfbp2 upregulation in hypertensive mice, which Cmpd17b normalized.
The findings position FPR agonism as a potential therapy for established essential hypertension by targeting both pressure control and renovascular remodeling, not just preventing damage.